{'fraction_non_alphanumeric': 0.0327455919395466, 'fraction_numerical': 0.020151133501259445, 'mean_word_length': 5.36, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[Experiences with cis-dichlorodiaminoplatinum (II) in the treatment of advanced solid tumors].

Cis-Dichlorodiammineplatinum (II) was administered in 23 patients with far advanced solid malignancies using a dose schedule of 50 mg/m2 every 3 weeks. All patients had previously progressive disease using conventional cytotoxic therapies. More than 50% of the patients had been pretreated with at least 4 different drugs. 9 patients, additionally, had been irradiated. In 4 instances there was objective tumor regression (duration: 1 to 4 months), in 7 patients tumor progression could be stopped for at least one month, 12 patients did not respond. By sufficient fluid administration combined with electrolyte substitution, furosemide and mannitol, no severe toxic side effects could be observed.